Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents.
APA
Tanvetyanon T (2026). Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents.. Journal of thoracic disease, 18(1), 48. https://doi.org/10.21037/jtd-2025-1951
MLA
Tanvetyanon T. "Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents.." Journal of thoracic disease, vol. 18, no. 1, 2026, pp. 48.
PMID
41660442
같은 제1저자의 인용 많은 논문 (3)
- Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis.
- Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab Consolidation.
- Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.